VISION
Regimen
- Experimental
- tepotinib
- Control
- none
Population
MET exon 14 skipping NSCLC
Key finding
ORR 46% by liquid biopsy, 48% by tissue; mDOR ~11 mo; first MET-selective approval evidence
Source: PMID 32469185
Timeline
- Enrollment start: 2016-09-13 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.107)
- CSCO NSCLC 2025 ⚠️ OCR source